Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 3/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 4/20 | 0.43 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16221826 | 0.93 | F2 (0.55) | F2TERTPOLBTK1P2RY2 | |
| SCHEMBL27062508 | 0.89 | DTYMK (0.55) | F2TERTPOLBTK1DTYMK | |
| SCHEMBL24239526 | 0.88 | TERT (0.57) | F2TERTPOLBTK1P2RY2 | |
| SCHEMBL24221447 | 0.88 | F2 (0.52) | F2TERTPOLBTK1P2RY2 | |
| SCHEMBL17973870 | 0.88 | F2 (0.51) | F2TERTPOLBTK1P2RY2 | |
| SCHEMBL17775300 | 0.88 | F2 (0.51) | F2TERTPOLBTK1P2RY2 | |
| SCHEMBL18925768 | 0.88 | F2 (0.51) | F2TERTPOLBTK1P2RY2 | |
| SCHEMBL20024805 | 0.88 | F2 (0.51) | F2TERTPOLBTK1P2RY2 | |
| SCHEMBL17243679 | 0.88 | F2 (0.51) | F2TERTPOLBTK1P2RY2 | |
| SCHEMBL26220716 | 0.88 | F2 (0.51) | F2TERTPOLBTK1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026353-A1 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | IONIS PHARMACEUTICALS, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026353-A1 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | SCN2A, SCN1A, SCN1B | F2 4729/4885TERT 4106/4885POLB 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.